David M. Ross
Impact in
- Hematology top 0.2%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 126
- Chronic Myeloid Leukemia Treatments 92
- Acute Myeloid Leukemia Research 43
- Genetics 107
- Chronic Lymphocytic Leukemia Research 56
- Myeloproliferative Neoplasms: Diagnosis and Treatment 52
- Co-authors
- Timothy P. Hughes (56 shared papers)Susan Branford (37 shared papers)David T Yeung (33 shared papers)John F. Seymour (9 shared papers)Andrew Grigg (14 shared papers)Anthony K. Mills (8 shared papers)Robin Filshie (7 shared papers)Deborah L. White (13 shared papers)
- Journals
- Blood (57 papers)Leukemia (9 papers)Pathology (6 papers)HemaSphere (5 papers)Blood Advances (4 papers)
- Partner nations
- AustraliaUnited StatesGermany
In The Last Decade
David M. Ross
130 papers receiving 3.1k citations
David M. Ross's Hit Papers
Peers
Comparison fields: 5 of 87
- Hematology 2.5k
- Genetics 1.9k
- Rheumatology 1.0k
- Pathology and Forensic Medicine 295
- Oncology 410
Countries citing papers authored by David M. Ross
This map shows the geographic impact of David M. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Ross more than expected).
Fields of papers citing papers by David M. Ross
This network shows the impact of papers produced by David M. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Ross. The network helps show where David M. Ross may publish in the future.
Co-authors
The 25 scholars most cited alongside David M. Ross, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 147 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study Hit paper breakdown → | 2013 | 512 |
| 2 | 2016 | 230 | |
| 3 | 2017 | 209 | |
| 4 | 2010 | 196 | |
| 5 | 2014 | 139 | |
| 6 | 2013 | 121 | |
| 7 | 2018 | 106 | |
| 8 | 2014 | 91 | |
| 9 | 2006 | 58 | |
| 10 | 2020 | 57 | |
| 11 | 2018 | 57 | |
| 12 | 2020 | 52 | |
| 13 | 2021 | 49 | |
| 14 | 2018 | 42 | |
| 15 | 2021 | 41 | |
| 16 | 2017 | 41 | |
| 17 | 2010 | 39 | |
| 18 | 2012 | 38 | |
| 19 | 2019 | 31 | |
| 20 | 2019 | 31 |
About David M. Ross
David M. Ross is a scholar working on Hematology, Genetics, Rheumatology, Molecular Biology and Public Health, Environmental and Occupational Health, having authored 147 papers that have together received 3.1k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (92 papers), Chronic Lymphocytic Leukemia Research (56 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (52 papers), Eosinophilic Disorders and Syndromes (43 papers), Acute Myeloid Leukemia Research (43 papers), Acute Lymphoblastic Leukemia research (11 papers), Kruppel-like factors research (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Hematology (2.5k citations), Genetics (1.9k citations), Rheumatology (1.0k citations), Pathology and Forensic Medicine (295 citations) and Oncology (410 citations). David M. Ross has collaborated with scholars based in Australia, United States and Germany. Frequent co-authors include Timothy P. Hughes, Susan Branford, David T Yeung, John F. Seymour, Andrew Grigg, Anthony K. Mills, Robin Filshie, Deborah L. White, Christopher Arthur and Anthony P. Schwarer. Their work appears in journals such as Blood, Leukemia, Pathology, HemaSphere and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.